IPP Bureau
Moderna expands Its mRNA pipeline with new development programs
By IPP Bureau - February 20, 2022
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Poxel’s PXL065 granted FDA fast track designation for X-linked adrenoleukodystrophy
By IPP Bureau - February 20, 2022
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Hinduja Global Solutions bags contract from the UK Health Security Agency to provide critical services
By IPP Bureau - February 20, 2022
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Aizon’s CEO John Vitalie named one of the top 25 Biotech CEOs of 2022
By IPP Bureau - February 19, 2022
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector
cbdMD becomes first American CBD brand to receive UK validation
By IPP Bureau - February 19, 2022
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
By IPP Bureau - February 19, 2022
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Jagsonpal Pharma inks agreement with Suvinys Developers
By IPP Bureau - February 19, 2022
Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.
Amneal expands injectables portfolio with four new products
By IPP Bureau - February 19, 2022
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Piramal Pharma appoints Amyra Dastur as brand ambassador for lacto calamine range
By IPP Bureau - February 19, 2022
The brand has added a range of exciting new products especially formulated for oily skin.
Tremfya achieves greater clinical responses in patients with ulcerative colitis
By IPP Bureau - February 19, 2022
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation
By IPP Bureau - February 19, 2022
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
Covid-19 fuels innovative PCR-based detection methods
By IPP Bureau - February 19, 2022
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
EC approves Tepmetko to treat non-small cell lung cancer
By IPP Bureau - February 19, 2022
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Natco Q3FY22 PAT up 27% to Rs 80 Cr
By IPP Bureau - February 19, 2022
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
UAE to recognise Indian pharma products within three months
By IPP Bureau - February 19, 2022
The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.
